Cantor Fitzgerald reiterated their overweight rating on shares of Prothena (NASDAQ:PRTA – Free Report) in a report published on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $129.00 price target on the biotechnology company’s stock. Several other equities analysts have also weighed in on PRTA. JMP Securities lifted their target price on shares of Prothena […]
Prothena Co. plc (NASDAQ:PRTA – Get Free Report) insider Hideki Garren sold 2,000 shares of the firm’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $58.74, for a total transaction of $117,480.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which […]
Prothena Co. plc (NASDAQ:PRTA – Get Free Report) COO Brandon S. Smith sold 4,000 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $58.71, for a total value of $234,840.00. The sale was disclosed in a filing with the Securities & Exchange Commission, […]
HC Wainwright restated their buy rating on shares of Prothena (NASDAQ:PRTA – Free Report) in a research report sent to investors on Friday, Benzinga reports. HC Wainwright currently has a $90.00 price objective on the biotechnology company’s stock. Other analysts also recently issued research reports about the stock. SVB Leerink reaffirmed an outperform rating on […]
HC Wainwright restated their buy rating on shares of Prothena (NASDAQ:PRTA – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $90.00 target price on the biotechnology company’s stock. Other equities research analysts have also issued reports about the company. Cantor Fitzgerald restated an overweight rating and set a $129.00 […]